Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × iberdomide × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 15 Recurrence 1 Neuroblastoma 1 Lymphoma, Non-Hodgkin 1 Lymphoma, B-Cell 1 Ganglioneuroblastoma 1

Interventions

Dexamethasone 12 Cyclophosphamide 12 pembrolizumab 11 Rituximab 11 venetoclax 9 fludarabine 9 pomalidomide 8 Lenalidomide 7 Gemcitabine 6 Cytarabine 6 Calcium Dobesilate 6 glofitamab 5 Temozolomide 5 Nivolumab 5 Etoposide 5 Bevacizumab 5 selinexor 4 ruxolitinib 4 obinutuzumab 4 daratumumab 4 carfilzomib 4 Doxorubicin 4 Capecitabine 4 Azacitidine 4 zanubrutinib 3 tisagenlecleucel 3 elotuzumab 3 belantamab mafodotin 3 atezolizumab 3 Vincristine 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06215118 2026-02-05

MagnetisMM-30

Pfizer

Phase 1 Recruiting

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡